Navigation Links
Genetic Research Offers Insights Into Form of Malaria
Date:10/8/2008

P. vivax causes 300 million cases of the disease each year

WEDNESDAY, Oct. 8 (HealthDay News) -- The genetic structure of the malaria-causing Plasmodium vivax parasite has been described by an international team of researchers, who said the information could help in the fight against malaria.

The majority of research into malaria has focused on the Plasmodium falciparum parasite, which causes the most virulent form of the disease. But P. vivax and other parasites of the same genus as P. falciparum also cause malaria.

It's believed that P. vivax causes nearly 300 million cases of malaria worldwide each year. While it is rarely fatal, P. vivax can cause severe malaria and resistance to some drugs, the researchers said.

The U.S. Institute for Genomic Research-led study found that P. vivax is far more similar to P. falciparum than expected. The researchers identified only 150 genes specific to P. vivax.

The study also found that P. vivax may have unique routes of invasion for penetrating blood cells in which the parasite resides and multiples during its life cycle. These alternative routes of infection haven't been noted in previous research and the genetic information necessary for this to happen is written in the genome of P. vivax, the researchers said.

The findings are published in the Oct. 9 issue of Nature.

Even though P. vivax causes 300 million cases of malaria each year in countries such as Brazil, India and Papua New Guinea, there has been a tendency to underestimate the importance of research into this form of malaria, the study authors noted.

They said research into P. vivax should be included in the funding schedules of the nations leading the global fight against malaria.

More information

The U.S. Centers for Disease Control and Prevent
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved

Page: 1 2

Related medicine news :

1. Many Parents Share Genetic Test Findings With Kids
2. Genetic predisposition increases childhood asthma risk
3. New Alzheimers findings: High stress and genetic risk factor lead to increased memory decline
4. Test Spots Genetic Damage Done by Smoking
5. Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds
6. Scientists highlight benefits of genetic research in sport, but warn of ethical concerns
7. Genetics Hold Promise, Challenges for Cancer Care
8. Researchers genetically engineer micro-organisms into tiny factories
9. Study Questions Genetic Screening for Treatable Diseases
10. Researchers provide genetic associations from a genome-wide scan for cardiovascular disease traits
11. Genetic variation affects smoking cessation treatment

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)... Tenn., Nov. 30 During this time o...holidays. For a loved one with Alzheimer,s disease...ends oftentimes struggle with appropriate gift ite...ading providers of senior living residences in the..., offers these suggestions. ,, A listening dev...
(Date:11/30/2009)...se Control and Prevention estimate that well over ...ed with HIV/AIDS. New research from North Carolina...d are minorities and do not have health insurance,...o facilitate education and prevention efforts in m...ch, which analyzed 90,000 HIV patient hospital vis...
(Date:11/30/2009)...thor of "My Two-Year Old Eats Octopus," ...to eat everything. , (PRW... in your house? Do you find yourself acting as a ...ine videos – one focusing on packing lunches...rs for real-life parents’ questions – ...
(Date:11/30/2009)...Colo., Nov. 30 Baxa Corporation is... what "culture of safety" means in today,s pharmac... "Creating a Culture of Safety in Pharmacy ," fea...ssing their experiences with culture of safety, wh...cy and the role of technology in enabling or inhib...
(Date:11/30/2009)..., Nov. 30 Stryker Corpor...agreement to acquire privately held Ascent Health...ocessing and remanufacturing of medical devices in... Stryker will acquire Ascent Healthcare Solutions ...losing is conditioned on the expiration or termina...
Breaking Medicine News(10 mins):Health News:Gift Ideas for Loved Ones with Alzheimer's/Dementia 2Health News:Research highlights need for national HIV strategy 2Health News:New Videos Help Parents of Picky Eaters 2Health News:New Videos Help Parents of Picky Eaters 3Health News:Baxa to Sponsor ASHP Midday Symposium: Creating a Culture of Safety in Pharmacy, A Panel Discussion on Lessons Learned 2Health News:Baxa to Sponsor ASHP Midday Symposium: Creating a Culture of Safety in Pharmacy, A Panel Discussion on Lessons Learned 3Health News:Stryker Announces Definitive Agreement To Acquire Ascent Healthcare Solutions 2Health News:Stryker Announces Definitive Agreement To Acquire Ascent Healthcare Solutions 3
...) today announced third quarter and nine months re...ber 31, 2007, Hawkins reported sales,increased 30....ame period a,year ago. Net income for the quarter ...For the nine months ended December 31, 2007, Hawki...
...(Nasdaq: MLAB ) today announced that its Board of...ividend of ten cents per share of common,stock, pa...at the close of,business on February 25, 2008., M...ews release contains forward-looking statements wh...
... (both children and adults) when given gadolinium ... pre-medicated with corticosteroids and antihistam...earchers at the University of Michigan Health Syst...t agents, said Jonathan R. Dillman, MD, lead autho...
... Spending Cuts, ALEXANDRIA, Va., Feb. 8 Presiden...th programs vital to the future of,health and heal...on cut in,Medicaid, the nation,s single largest pa...end on, ranging from poison,control hotlines to fu...
....uk ), the,online ,front door, to the NHS, launche...sense of the stories appearing in the news about m...oices,( http://www.nhs.uk/News/Pages/NewsIndex.asp...g of the science. It,also provides an authoritativ...
...nger is suppressed , , FRIDAY, Feb. 8 (Hea...arriage is communication, and new research now not...tudy of Midwestern couples finds that those who fe...orst thing to do is to keep it in, not talk about ...
Other Medicine News:Health News:Hawkins, Inc. Reports Third Quarter, Nine Months Fiscal 2008 Results 2Health News:Hawkins, Inc. Reports Third Quarter, Nine Months Fiscal 2008 Results 3Health News:Hawkins, Inc. Reports Third Quarter, Nine Months Fiscal 2008 Results 4Health News:Allergic-like reactions occur in premedicated patients 2Health News:Bush Budget Cuts Federal Health Programs Vital to the Health of All Children 2Health News:Bush Budget Cuts Federal Health Programs Vital to the Health of All Children 3Health News:Mutual Resentment in Marriage Can Be Deadly 2Health News:Mutual Resentment in Marriage Can Be Deadly 3
(Date:11/30/2009).... 30 Cytokine PharmaSciences, Inc.... of CPSI-2364, its orally active, small-molecule i...pro-inflammatory cytokines. Results of the safety... volunteers confirm the safety of this compound in... subjects completed the study, including those rec...
(Date:11/30/2009)...PRNewswire/ -- The Simmons law firm,s Trent Miracl...ing thousands of women that were seriously injured...rol pill manufactured and marketed by Bayer Pharma...istrict Litigation has ordered that all federal Ya...idated and centralized for pretrial litigation in ...
(Date:11/30/2009)... 30 According to Millennium Resear...chnology market intelligence, the nearly $1.2 bill...most 5% over 2008 as patients chose to delay or fo... The market will, however, begin recovery in 2010,...ion growth rates of over 15%. MRG,s facial injecta...
Breaking Medicine Technology:Cytokine PharmaSciences Completes Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364 2Simmons Firm's Partner Trent Miracle Chosen to Help Lead National Litigation Against Bayer 2Facial Injectables Emerge From the Recession 2Facial Injectables Emerge From the Recession 3Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 1Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 2Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 3Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 4Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 5Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 6Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 7Hard to Treat Diseases Inc 28HTDS 29 and Landstar Inc 28LDSR 29 Cash Reward 56529 1Hard to Treat Diseases Inc 28HTDS 29 and Landstar Inc 28LDSR 29 Cash Reward 56529 2Hard to Treat Diseases Inc 28HTDS 29 and Landstar Inc 28LDSR 29 Cash Reward 56529 3Hard to Treat Diseases Inc 28HTDS 29 and Landstar Inc 28LDSR 29 Cash Reward 56529 4Prometheus Announces Co Pay Assistance Savings Program for LOTRONEX 28R 29 28alosteron HCl 29 Tablets 56526 1Prometheus Announces Co Pay Assistance Savings Program for LOTRONEX 28R 29 28alosteron HCl 29 Tablets 56526 2Prometheus Announces Co Pay Assistance Savings Program for LOTRONEX 28R 29 28alosteron HCl 29 Tablets 56526 3Prometheus Announces Co Pay Assistance Savings Program for LOTRONEX 28R 29 28alosteron HCl 29 Tablets 56526 4
...MELBOURNE, Australia, Feb. 11 Phosphagenics,Limit...PGNY) and Nestle,Nutrition (Nestle) today announce... establish the efficacy of Phosphagenics, Phospha ...vancing at three sites in Adelaide,Australia., Ba...ants, the,double-blind phase 2 trial, which is ful...
...BOULDER, Colo., and MONTREAL, Feb. 11 ,Pharmion (N...y announced that,the European Medicines Agency (EM...CD0103, a histone deacetylase (HDAC) inhibitor, as...acute myelogenous leukemia in the,European Union (...duct be,intended for the treatment of life-threate...
Other Medicine Technology:Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 2Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 3Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 4Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 2Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 3Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 4
VascoScrew E 8/60 M
VascoScrew P 6/60 M
VascoScrew E 6/60 S
VascoScrew E 5/60 PU M
Medicine Products: